Vaxcyte Inc
USUSDVaxcyte Inc (US:PCVX) — Biotechnology: Biological Products (No Diagnostic Substances). Nombre de places boursières sur lesquelles les actions de la société sont cotées : 2. Sur cette page : cours et graphique, dividendes, principaux actionnaires et historique du nombre d'actions.
À propos de l'entreprise
- Site Web
- vaxcyte.com
- Relations avec les Investisseurs
- investors.vaxcyte.com/
- Secteur
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Siège Social
- SAN CARLOS, United States
- PDG
- Grant E. Pickering
- Employés
- 507
- Actions en Circulation
- 148.81 M au 2026-08-03
- Flottant
- 136.44 M
- Capitalisation Boursière
- 8.34 Md USD
- Initiés
- 0.5%
- Investisseurs Institutionnels
- 113.47%
- Secteur d'Activité (SIC)
- Biological Products, (No Diagnostic Substances)
- ISIN
- US92243G1085
- LEI
- 254900M7NMHTGASX8D95
- P/E
- perte
- FCF
- −894 M USD
- Dette
- ?
- Résultats et FCF — pour les 12 mois à 30.06.2026 (dernier rapport de l'entreprise).
- NAV
Description
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Principaux Actionnaires
| Détenteur | Participation | Actions | Date du Rapport |
|---|---|---|---|
| FMR, LLC | 14.01% | 20.85 M | 2026-06-30 |
| Jupiter Topco LLC | 12.07% | 17.97 M | 2026-06-30 |
| T. Rowe Price Investment… | 8.2% | 12.21 M | 2026-06-30 |
| Blackrock Inc. | 8.11% | 12.07 M | 2026-06-30 |
| RA Capital Management, L… | 7.71% | 11.47 M | 2026-06-30 |
| Wellington Management Gr… | 4.71% | 7 M | 2026-06-30 |
| Vanguard Portfolio Manag… | 4.43% | 6.59 M | 2026-06-30 |
| Vanguard Capital Managem… | 4.27% | 6.35 M | 2026-06-30 |
| State Street Corporation | 3.6% | 5.35 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.08% | 4.59 M | 2026-06-30 |
| Deep Track Capital, Lp | 2.89% | 4.3 M | 2026-06-30 |
| T. ROWE PRICE CAPITAL AP… | 2.69% | 4.01 M | 2026-06-30 |
| iShares Trust-iShares Ru… | 2.27% | 3.37 M | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 2.23% | 3.31 M | 2026-06-30 |
| Fidelity Rutland Square… | 2.11% | 3.14 M | 2026-07-31 |
| JANUS INVESTMENT FUND-Ja… | 1.8% | 2.68 M | 2026-06-30 |
| VANGUARD SPECIALIZED FUN… | 1.57% | 2.34 M | 2026-07-31 |
| SPDR SERIES TRUST-State… | 1.55% | 2.31 M | 2026-08-31 |
| JANUS INVESTMENT FUND-Ja… | 1.53% | 2.27 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.28% | 1.91 M | 2026-06-30 |
| GUGGENHIME ANDREW (Presi… | ≈0.11% | 167 026 | 2026-08-03 |
| WASSIL JAMES (Chief Oper… | ≈0.1% | 145 435 | 2026-09-09 |
| DHALIWAL HARPREET S. (Of… | ≈0.05% | 76 756 | 2026-08-05 |
| JODAR LUIS (Officer) | ≈0.04% | 52 632 | 2026-09-04 |
| EYDELMAN MIKHAIL (Genera… | ≈0.03% | 41 620 | 2025-03-05 |
| COWAN ELVIA (Officer) | ≈0.02% | 28 975 | 2026-04-07 |
| LUKATCH HEATH SCOTT (Dir… | ≈0.01% | 19 481 | 2026-06-15 |
| LOXAM TERI (Director) | ≈0.01% | 12 481 | 2026-06-15 |
| PAYA CARLOS V (Director) | ≈0.01% | 12 481 | 2026-06-15 |
| PICKERING GRANT E (Chief… | — | — | 2026-07-27 |
